Brief: FDA Grants Genfit’s GNS561 Orphan Drug Designation

Genfit SA

13/09/2022 21:14

Sept 13 (Reuters) - Genfit SA  GNFT.PA :
    * FDA GRANTS GENFIT’S GNS561 ORPHAN DRUG DESIGNATION FOR THE
TREATMENT OF CHOLANGIOCARCINOMA
    * GENFIT SA- A PHASE 2 TRIAL IS EXPECTED TO START IN Q4
2022, WITH
A FIRST PATIENT VISIT EXPECTED IN Q1 2023

Source text for Eikon:  ID:nGNX2TK1yf 
Further company coverage:  GNFT.PA 

 ((Reuters.Briefs@thomsonreuters.com;))